RG6505
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other RAS (pan-RAS, RAS-mutant tumors) drugs
Daraxonrasib, BPI-572270. Compare all 3 RAS (pan-RAS, RAS-mutant tumors) drugs
2 other tracked programmes target this mechanism.
This drug's own stage for Advanced Solid Tumors: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RG6505: this drug | Stage not on record | Undisclosed | RAS (pan-RAS, RAS-mutant tumors) | not yet graded | No reviewed efficacy summary in this indication | |
| Daraxonrasib (Rasonque) | Approved(overall) | Small molecule | pan-RAS, RAS (pan-RAS, RAS-mutant tumors) | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| AZD4956 | Phase 1/2(overall) | Small molecule | POLQ (DNA polymerase theta) | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986517 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986548 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BPI-572270 | Phase 1/2(overall) | Small molecule | RAS (pan-RAS, RAS-mutant tumors) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HRS-6768 | Phase 1/2 | Undisclosed | Fibroblast Activation Protein (FAP) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8364 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Palacaparib | Phase 1/2(overall) | Small molecule | PARP1 inhibitor (next-gen) | not yet graded | No reviewed efficacy summary in this indication | |
| REGN10597 | Phase 1/2 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1681 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4298 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4375 | Phase 1/2 | Antibody–drug conjugate | Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4610 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7787 | Phase 1/2 | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-9803 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-188 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-505 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-253 | Phase 1 | Biologic (subtype unspecified) | c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986500 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5533524 | Phase 1 | Antibody–drug conjugate | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-6093 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-87890387 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-89862175 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| MP0310 | Phase 1 | Protein / enzyme therapeutic | FAP x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3821 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4685 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4849 | Phase 1 | Antibody–drug conjugate | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7782 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-168 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| YS-ON-001 | Phase 1 | Biologic (subtype unspecified) | TLR3 (poly I:C adjuvant) | not yet graded | No reviewed efficacy summary in this indication | |
| 225Ac-ETN029 | —(overall) | Radioligand Therapy (actinium-225) | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| AAA614 | —(overall) | Radioligand Therapy | Fibroblast Activation Protein (FAP) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5863 | —(overall) | Multispecific antibody | Claudin 18.2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD9793 | —(overall) | Multispecific antibody | Glypican-3 (GPC3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986506 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GCJ904 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5460025 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08032560 | —(overall) | Small molecule | KAT6A/KAT6B and KAT7 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08046044 | —(overall) | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| RG6620 | —(overall) | Undisclosed | KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| RG6648 | —(overall) | Antibody–drug conjugate | c-MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.